Literature DB >> 25583206

Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Yasunori Akutsu1, Hisahiro Matsubara2.   

Abstract

Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness. The most effective treatment modality for esophageal cancer, particularly T4 esophageal cancer, is chemoradiotherapy (CRT). Some T4 patients show long-term survival after receiving CRT, suggesting that even T4 esophageal cancer can be cured with this modality. Although surgery is performed after CRT in some T4 cases, its prognostic benefit is controversial. In this paper, we review the status of CRT and conversion surgery as well as the development of new regimens and discuss the future prospects of CRT in the treatment of T4 esophageal cancer in Japan.

Entities:  

Keywords:  Chemoradiotherapy; Esophageal cancer; Japan; Surgery; T4

Mesh：

Substances：

Year:  2015        PMID： 25583206     DOI： 10.1007/s00595-015-1116-4

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.549


  41 in total

1.  Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs.

Authors:  K Ikeda; K Ishida; N Sato; K Koeda; K Aoki; Y Kimura; T Iwaya; S Ogasawara; S Iijima; R Nakamura; N Uesugi; C Maesawa; K Saito
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

2.  Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma.

Authors:  T Noguchi; H Moriyama; S Wada; S Takeno; M Wakisaka; H Mori; Y Uchida
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

3.  Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma.

Authors:  Junko Kuroda; Masashi Yoshida; Masaki Kitajima; Akio Yanagisawa; Toshiki Matsubara; Toshiharu Yamaguchi; Yoshiyuki Osamura; Keiichirou Ohta; Keisuke Kubota; Yoshifumi Beck; Yuichi Yamashita
Journal:  J Gastroenterol Hepatol       Date:  2012-04       Impact factor: 4.029

4.  Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience.

Authors:  Hideaki Shimada; Tooru Shiratori; Shinichi Okazumi; Hisahiro Matsubara; Yoshihiro Nabeya; Kiyohiko Shuto; Yasunori Akutsu; Hideki Hayashi; Kaichi Isono; Takenori Ochiai
Journal:  J Am Coll Surg       Date:  2007-09-17       Impact factor: 6.113

5.  Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma.

Authors:  Shunsuke Imanishi; Kiyohiko Shuto; Tomoyoshi Aoyagi; Tsuguaki Kono; Hiroshige Saito; Hisahiro Matsubara
Journal:  Dig Surg       Date:  2013-07-19       Impact factor: 2.588

6.  Evaluation of local invasion by oesophageal carcinoma--a prospective study of prone computed tomography scanning.

Authors:  J Wayman; S Chakraverty; S M Griffin; G J Doyle; M J Keir; W Simpson
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

7.  Prognosis of esophageal cancers preoperatively staged to be locally invasive (T4) by endoscopic ultrasound (EUS): a multicenter retrospective cohort study.

Authors:  A Chak; M Canto; H Gerdes; C J Lightdale; R H Hawes; M J Wiersema; G Kallimanis; T L Tio; T W Rice; H W Boyce
Journal:  Gastrointest Endosc       Date:  1995-12       Impact factor: 9.427

8.  Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography.

Authors:  Bunichi Ito; Yasumasa Niwa; Nobuhiro Ando; Naoki Ohmiya; Ryoji Miyahara; Akira Ohashi; Akihiro Itoh; Yoshiki Hirooka; Hidemi Goto
Journal:  Eur J Radiol       Date:  2005-06       Impact factor: 3.528

9.  Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.

Authors:  M Yano; T Tsujinaka; H Shiozaki; M Inoue; Y Doki; M Yamamoto; E Tanaka; T Inoue; M Monden
Journal:  J Surg Oncol       Date:  1999-01       Impact factor: 3.454

10.  A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).

Authors:  Katsuhiko Higuchi; Wasaburo Koizumi; Satoshi Tanabe; Tohru Sasaki; Chikatoshi Katada; Hiromichi Ishiyama; Kazushige Hayakawa
Journal:  Radiother Oncol       Date:  2008-04-09       Impact factor: 6.280
View more
  13 in total

1.  Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer.

Authors:  Hideyuki Morimoto; Yushi Fujiwara; Shigeru Lee; Kosuke Amano; Masako Hosono; Yukio Miki; Harushi Osugi
Journal:  Jpn J Radiol       Date:  2017-10-28       Impact factor: 2.374

2.  New classification for the thoracic paraaortic lymph nodes of patients with esophageal squamous cell carcinoma.

Authors:  Masaaki Yamamoto; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-08-23       Impact factor: 2.549

3.  MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer.

Authors:  Kota Momose; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

Review 4.  Definitive chemoradiotherapy.

Authors:  Michael Stahl; Wilfried Budach
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Norma E Farrow; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole
Journal:  Ann Thorac Surg       Date:  2019-07-26       Impact factor: 4.330

Review 6.  Surgical strategies for treatment of clinical T4 esophageal cancer in Japan.

Authors:  Kazuhiko Yamada; Kyoko Nohara; Naoki Enomoto; Hitomi Wake; Syusuke Yagi; Masayoshi Terayama; Daiki Kato; Chizu Yokoi; Yasushi Kojima; Hidetsugu Nakayama; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2021-12-31

7.  Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.

Authors:  Kotaro Sugawara; Koichi Yagi; Yasuhiro Okumura; Masato Nishida; Susumu Aikou; Hiroharu Yamashita; Hideomi Yamashita; Yasuyuki Seto
Journal:  Int J Clin Oncol       Date:  2019-12-11       Impact factor: 3.402

8.  Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair.

Authors:  Masanobu Nakajima; Hiroto Muroi; Maiko Kikuchi; Satoru Yamaguchi; Kinro Sasaki; Takashi Tsuchioka; Yusuke Takei; Ikuko Shibasaki; Hirotsugu Fukuda; Hiroyuki Kato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-09-15

Review 9.  Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review.

Authors:  Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Masaaki Motoori; Yutaka Kimura; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  Ann Gastroenterol Surg       Date:  2018-12-13

10.  Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma.

Authors:  Yasuo Hamamoto; Masanori Nojima; Yu Aoki; Takeshi Suzuki; Kenta Kawasaki; Kenro Hirata; Yasutaka Sukawa; Akira Kasuga; Hirofumi Kawakubo; Hiroya Takeuchi; Koji Murakami; Hiromasa Takaishi; Takanori Kanai; Yuko Kitagawa
Journal:  Esophagus       Date:  2017-05-23       Impact factor: 4.230
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.